ZA945939B - Insulin formulation - Google Patents

Insulin formulation

Info

Publication number: ZA945939B
Authority: ZA; South Africa
Prior art keywords: insulin; formulation; zinc; total; present
Prior art date: 1993-08-13

Application number

ZA945939A

Other languages

English (en)

Inventor

James Arthur Hoffmann

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-13

Filing date

1994-08-08

Publication date

1996-02-08

1994-08-08 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1996-02-08 Publication of ZA945939B publication Critical patent/ZA945939B/xx

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 12
238000009472 formulation Methods 0.000 title abstract 7
239000000203 mixture Substances 0.000 title abstract 7
102000004877 Insulin Human genes 0.000 title abstract 6
108090001061 Insulin Proteins 0.000 title abstract 6
229940125396 insulin Drugs 0.000 title abstract 6
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 2
239000011701 zinc Substances 0.000 abstract 2
229910052725 zinc Inorganic materials 0.000 abstract 2
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
102000007327 Protamines Human genes 0.000 abstract 1
108010007568 Protamines Proteins 0.000 abstract 1
239000013078 crystal Substances 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
230000005923 long-lasting effect Effects 0.000 abstract 1
229940048914 protamine Drugs 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
239000000725 suspension Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA945939A 1993-08-13 1994-08-08 Insulin formulation ZA945939B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/106,106 US5534488A (en)	1993-08-13	1993-08-13	Insulin formulation

Publications (1)

Publication Number	Publication Date
ZA945939B true ZA945939B (en)	1996-02-08

Family

ID=22309529

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA945939A ZA945939B (en)	1993-08-13	1994-08-08	Insulin formulation

Country Status (27)

Country	Link
US (1)	US5534488A (cs)
EP (1)	EP0646379B1 (cs)
JP (1)	JPH07149660A (cs)
KR (1)	KR950005324A (cs)
CN (1)	CN1109364A (cs)
AT (1)	ATE207761T1 (cs)
AU (1)	AU674975B2 (cs)
BR (1)	BR9403204A (cs)
CA (1)	CA2129763A1 (cs)
CO (1)	CO4230235A1 (cs)
CZ (1)	CZ193794A3 (cs)
DE (1)	DE69428860T2 (cs)
DK (1)	DK0646379T3 (cs)
ES (1)	ES2164691T3 (cs)
HU (1)	HUT67853A (cs)
IL (1)	IL110581A0 (cs)
NO (1)	NO942959L (cs)
NZ (1)	NZ264197A (cs)
PE (1)	PE14495A1 (cs)
PH (1)	PH30757A (cs)
PL (1)	PL177002B1 (cs)
PT (1)	PT646379E (cs)
RU (1)	RU2135205C1 (cs)
TW (1)	TW326394B (cs)
UA (1)	UA27874C2 (cs)
YU (1)	YU50494A (cs)
ZA (1)	ZA945939B (cs)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5578238A (en) *	1992-10-30	1996-11-26	Lord Corporation	Magnetorheological materials utilizing surface-modified particles
AR002976A1 (es) *	1995-03-31	1998-05-27	Lilly Co Eli	Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
CO4970787A1 (es) *	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP1396272A1 (en) *	1997-12-23	2004-03-10	Eli Lilly & Company	Insoluble Insulin Compositions for Controlling Blood Glucose
US6956021B1 (en) *	1998-08-25	2005-10-18	Advanced Inhalation Research, Inc.	Stable spray-dried protein formulations
AU5454200A (en) *	1999-06-29	2001-01-31	Eli Lilly And Company	Protamine-free insoluble acylated insulin compositions
US7678364B2 (en)	1999-08-25	2010-03-16	Alkermes, Inc.	Particles for inhalation having sustained release properties
DK1265630T3 (da) *	2000-03-24	2006-10-09	Genentech Inc	Anvendelse af insulin til behandling af brusksygdomme
EP1247283B1 (en)	2000-10-06	2006-08-16	The Adviser - Defence Research & Development Organisation	A magneto sensitive fluid composition and a process for preparation thereof
EP1344229B1 (en) *	2000-11-29	2008-03-05	The Adviser Defence Research & Development Organisation, Ministry of Defence, Government of India	A magnetorheological fluid composition and a process for preparation thereof
CN100439397C (zh) *	2001-02-09	2008-12-03	基因技术股份有限公司	Igf-1的结晶
DE10114178A1 (de) *	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CA2471144C (en)	2002-01-09	2011-06-07	Emisphere Technologies, Inc.	Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
RU2251426C1 (ru) *	2003-09-18	2005-05-10	Цыганков Владимир Владимирович	Способ получения инсулина из природного источника и инсулин
CA2553392A1 (en) *	2004-01-16	2005-08-11	Biodel Inc	Sublingual drug delivery device
PL2319500T3 (pl) *	2004-03-12	2013-05-31	Biodel Inc	Szybko działające kompozycje do dostarczania leku
US20080085298A1 (en) *	2004-03-12	2008-04-10	Biodel, Inc.	Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en)	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
US20080248999A1 (en) *	2007-04-04	2008-10-09	Biodel Inc.	Amylin formulations
US20080096800A1 (en) *	2004-03-12	2008-04-24	Biodel, Inc.	Rapid mucosal gel or film insulin compositions
ES2729825T3 (es)	2004-05-06	2019-11-06	Emisphere Tech Inc	Formas poliméricas cristalinas de N-[8-(2-hidroxibenzoil)amino]caprilato monosódico
CA2566161C (en) *	2004-05-14	2013-10-01	Emisphere Technologies, Inc.	Aryl ketone compounds and compositions for delivering active agents
CN103223160B (zh)	2004-07-19	2015-02-18	比奥孔有限公司	胰岛素-低聚物共轭物,制剂及其用途
CA2573856A1 (en)	2004-08-03	2006-02-16	Emisphere Technologies, Inc.	Antidiabetic oral insulin-biguanide combination
US20060078623A1 (en) *	2004-08-13	2006-04-13	Emisphere Technologies, Inc.	Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
RU2288000C1 (ru) *	2005-04-27	2006-11-27	Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН)	Раствор инсулина для перорального введения
US8084420B2 (en) *	2005-09-29	2011-12-27	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US7713929B2 (en) *	2006-04-12	2010-05-11	Biodel Inc.	Rapid acting and long acting insulin combination formulations
JP2009533471A (ja) *	2006-04-12	2009-09-17	バイオデル，インコーポレイテッド	即効型および長時間作用型組合せインスリン製剤
WO2008112706A1 (en)	2007-03-13	2008-09-18	Nutrition 21, Inc.	Methods and compositions for the sustained release of chromium
WO2009002867A2 (en)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US9241908B2 (en)	2007-10-16	2016-01-26	Biocon Limited	Orally administrable solid pharmaceutical composition and a process thereof
US20090175840A1 (en) *	2008-01-04	2009-07-09	Biodel, Inc.	Insulin formulations for insulin release as a function of tissue glucose levels
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
US9060927B2 (en) *	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
KR101853606B1 (ko)	2009-07-06	2018-05-03	사노피-아벤티스 도이칠란트 게엠베하	메티오닌을 함유하는 수성 인슐린 제제
KR101337322B1 (ko)	2009-11-13	2013-12-06	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en)	2009-11-13	2015-04-13	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
WO2011103575A1 (en) *	2010-02-22	2011-08-25	Case Western Reserve University	Long-acting insulin analogue preparations in soluble and crystalline forms
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
ES2927800T3 (es)	2011-03-01	2022-11-11	Nutrition 21 Llc	Composición de insulina y cromo para el tratamiento y la prevención de diabetes, hipoglicemia y trastornos relacionados
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
AU2015359376B2 (en)	2014-12-12	2021-09-09	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
GB2564295A (en)	2016-02-11	2019-01-09	Nutrition 21 Llc	Chromium containing compositions for improving health and fitness

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2626228A (en) *	1945-05-17	1953-01-20	Novo Terapeutisk Labor As	Method of producing crystalline insulin
US2882202A (en) *	1950-04-05	1959-04-14	Novo Terapeutisk Labor As	Insulin crystal preparations and methods of producing them
US2882203A (en) *	1951-06-26	1959-04-14	Novo Terapeutisk Labor As	Injectable insulin preparation with protracted effect
US2849370A (en) *	1953-06-04	1958-08-26	Novo Terapeutisk Labortorium A	Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) *	1953-08-19	1963-08-27	Christensen Henry Marinus	Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) *	1953-11-13	1958-01-14	Novo Terapeutisk Labor As	Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) *	1953-11-14	1957-07-16	Novo Terapeutisk Labor As	Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) *	1957-07-18	1962-10-23	Nordisk Insulinlab	Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) *	1979-08-22	1981-03-12	Hoechst Ag, 6000 Frankfurt	Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3101382A1 (de) *	1981-01-17	1982-09-02	Hoechst Ag, 6000 Frankfurt	"verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
FI78616C (fi) *	1982-02-05	1989-09-11	Novo Industri As	Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
SU1131507A1 (ru) *	1982-05-28	1984-12-30	Черновицкий Ордена Трудового Красного Знамени Государственный Университет	Способ получени инсулина
DE3511269A1 (de) *	1985-04-12	1986-10-09	Veb Berlin-Chemie, Ddr 1199 Berlin	Verfahren zur reinigung von insulin
PH23446A (en) *	1986-10-20	1989-08-07	Novo Industri As	Peptide preparations
DE3827533A1 (de) *	1988-08-13	1990-02-15	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des diabetes mellitus

1993
- 1993-08-13 US US08/106,106 patent/US5534488A/en not_active Expired - Fee Related
1994
- 1994-08-04 HU HU9402287A patent/HUT67853A/hu unknown
- 1994-08-08 ZA ZA945939A patent/ZA945939B/xx unknown
- 1994-08-08 IL IL11058194A patent/IL110581A0/xx not_active IP Right Cessation
- 1994-08-08 PE PE1994248043A patent/PE14495A1/es not_active Application Discontinuation
- 1994-08-08 NZ NZ264197A patent/NZ264197A/en unknown
- 1994-08-08 BR BR9403204A patent/BR9403204A/pt not_active Application Discontinuation
- 1994-08-09 TW TW083107259A patent/TW326394B/zh active
- 1994-08-09 AT AT94305883T patent/ATE207761T1/de not_active IP Right Cessation
- 1994-08-09 CA CA002129763A patent/CA2129763A1/en not_active Abandoned
- 1994-08-09 EP EP94305883A patent/EP0646379B1/en not_active Expired - Lifetime
- 1994-08-09 RU RU94028671A patent/RU2135205C1/ru active
- 1994-08-09 PH PH48764A patent/PH30757A/en unknown
- 1994-08-09 PL PL94304600A patent/PL177002B1/pl unknown
- 1994-08-09 DE DE69428860T patent/DE69428860T2/de not_active Expired - Fee Related
- 1994-08-09 UA UA94085696A patent/UA27874C2/uk unknown
- 1994-08-09 KR KR1019940019550A patent/KR950005324A/ko not_active Abandoned
- 1994-08-09 NO NO942959A patent/NO942959L/no not_active Application Discontinuation
- 1994-08-09 ES ES94305883T patent/ES2164691T3/es not_active Expired - Lifetime
- 1994-08-09 DK DK94305883T patent/DK0646379T3/da active
- 1994-08-09 PT PT94305883T patent/PT646379E/pt unknown
- 1994-08-09 CO CO94035010A patent/CO4230235A1/es unknown
- 1994-08-10 CZ CZ941937A patent/CZ193794A3/cs unknown
- 1994-08-10 CN CN94109082A patent/CN1109364A/zh active Pending
- 1994-08-10 JP JP6188204A patent/JPH07149660A/ja not_active Withdrawn
- 1994-08-10 YU YU50494A patent/YU50494A/sh unknown
- 1994-08-12 AU AU70247/94A patent/AU674975B2/en not_active Ceased

Also Published As

Publication number	Publication date
NO942959D0 (no)	1994-08-09
HU9402287D0 (en)	1994-09-28
EP0646379A1 (en)	1995-04-05
CZ193794A3 (en)	1995-03-15
ATE207761T1 (de)	2001-11-15
YU50494A (sh)	1997-01-08
HUT67853A (en)	1995-05-29
PH30757A (en)	1997-10-17
CA2129763A1 (en)	1995-02-14
UA27874C2 (uk)	2000-10-16
PT646379E (pt)	2002-03-28
AU7024794A (en)	1995-02-23
NO942959L (no)	1995-02-14
DE69428860T2 (de)	2002-05-02
CO4230235A1 (es)	1995-10-19
ES2164691T3 (es)	2002-03-01
AU674975B2 (en)	1997-01-16
CN1109364A (zh)	1995-10-04
TW326394B (en)	1998-02-11
PL177002B1 (pl)	1999-09-30
DK0646379T3 (da)	2001-12-03
IL110581A0 (en)	1994-11-11
PL304600A1 (en)	1995-02-20
US5534488A (en)	1996-07-09
PE14495A1 (es)	1995-06-02
BR9403204A (pt)	1995-04-18
NZ264197A (en)	1997-01-29
DE69428860D1 (de)	2001-12-06
EP0646379B1 (en)	2001-10-31
RU2135205C1 (ru)	1999-08-27
KR950005324A (ko)	1995-03-20
JPH07149660A (ja)	1995-06-13

Publication	Publication Date	Title
PH30757A (en)	1997-10-17	Insulin formulation.
AU610636B2 (en)	1991-05-23	Stabilised human protein preparations
AU5707294A (en)	1994-08-15	3,3 diphenyl prop-2-yl amino acid derivatives and their use as tachykinin antagonists
IL72494A0 (en)	1984-11-30	Homologues of aprotinin with other aminoacids in position 15,instead of lysine,their preparation and pharmaceutical compositions containing them
GB9108652D0 (en)	1991-06-12	Immunoreactive compounds
WO1995013297A3 (en)	1995-06-15	Improved immunogenic compositions against human gastrin 17
WO1994001006A3 (en)	1994-03-31	Composition for use as a food or food supplement
CA2015186A1 (en)	1990-10-24	Nutrient composition
NZ228710A (en)	1992-10-28	Modified "echistatin" and anti-clotting pharmaceutical composition
AU8188087A (en)	1988-06-02	Variants of hirudin, their use and their preparation
AU2670495A (en)	1995-12-05	Ifn-beta liquid formulations
AU624079B2 (en)	1992-06-04	Novel fluorinated derivatives of amino acids usable more particularly as surfactants or cosurfactants and preparations for biomedical use incorporating these derivatives
AU6406590A (en)	1991-04-28	Porcine lactoferrin amino acid and cdna sequence
AU8375891A (en)	1992-03-19	Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
HU9402648D0 (en)	1994-11-28	3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine composition containing them as active componens
MD1714G2 (ro)	2002-03-31	Compoziţie terapeutică în formă de sirop, conţinând N-acetilcisteină
CA2168570A1 (en)	1995-03-30	Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid
AU2557288A (en)	1989-04-18	Synergistic antifungal protein and compositions containing same
CA2153071A1 (en)	1994-07-21	Derivatized calcitonins
EP0292302A3 (en)	1990-04-25	Human splenin
CA2247998A1 (en)	1997-09-04	Fragments of cr1 and their use